Document Detail

Pulmonary hypertension and beta blockers: where do we stand? Where are we going?
MedLine Citation:
PMID:  24488912     Owner:  NLM     Status:  In-Data-Review    
Pulmonary hypertension (PH) is a chronic, progressive debilitating disease and associated with poor prognosis despite the novel numerous treatment options. Beta-blockers constitute a cornerstone in left heart failure treatment; however, we still don't know the role of beta-blokers on PH and they are considered relatively contraindicated in patients with PH because of the possible negative effect on these patients' hemodynamics and exercise capacity. On the other hand, animal models of PH and non-randomized clinical trials have shown that beta-blockers may improve right ventricular function and prevent remodeling in the heart muscle. As it is well-known, right heart function is the main prognostic determinants of the PH. The purpose of this chapter is to present the use of beta-blockers for the treatment of PH, the purported mechanisms of action, previously conducted animal studies and clinical trials.
B Bugan; E C Roach
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European review for medical and pharmacological sciences     Volume:  18     ISSN:  1128-3602     ISO Abbreviation:  Eur Rev Med Pharmacol Sci     Publication Date:  2014 Jan 
Date Detail:
Created Date:  2014-02-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9717360     Medline TA:  Eur Rev Med Pharmacol Sci     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  229-34     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Gene expression analysis of lung cancer.
Next Document:  Increased sympathetic activation in patients with vasovagal syncope is associated with higher mean p...